Repligen Corp. Stock
Price
Target price
€154.50
€154.50
-1.120%
-1.75
-1.120%
€182.96
25.04.24 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Repligen Corp. Stock
A loss of -1.120% shows a downward development for Repligen Corp..
Repligen Corp. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
As a result the target price of 182 € shows a slightly positive potential of 17.8% compared to the current price of 154.5 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -1.120% | 4.675% | -9.437% | 13.270% | -7.816% | -14.357% | - |
| Opko Health Inc. | 1.930% | -0.982% | 23.925% | -16.662% | -19.340% | -68.292% | -43.684% |
| Catalent Inc. | 0.330% | -0.744% | 0.038% | 34.767% | 26.262% | -45.242% | 51.485% |
| Amicus Therapeutics Inc. | -3.550% | -4.040% | -11.215% | -12.844% | -28.571% | 14.458% | - |
Comments
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Stifel Nicolaus from $165.00 to $207.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at KeyCorp from $210.00 to $220.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $210.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat